EuroPCR 2022: Late-breaking Science Video Collection

Published: 13 May 2022

  • Views:

    Views Icon 1143
  • Likes:

    Heart Icon 7

Overview

Full programme

Part 2 of 2

EuroPCR 22: SYNERGY™ Non-inferior to BioMatrix NeoFlex in OCT SORT-OUT VIII

Michael Mæng

View Transcript Download Transcript

Overview

Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science trials and spotlight questions that could change treatment strategies in interventional cardiology.

Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

View from the Thoraxcenter

In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their take on the most anticipated late-breaking science form EuroPCR 2022.

Part 2

Expert Interviews

Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.
19 sessions
EuroPCR 22: AQVA Study Shows Superiority in QFR-Based Virtual PCI Arm Watch now
EuroPCR 22: Patient-Level Pooled Analysis of Ultrasound RDN in radiance-HTN SOLO & Trio Watch now
EuroPCR 22: Optimize PRO Interim Analysis Finds New Technique is "Best-in-Class" Watch now
EuroPCR 22: MASTER-DAPT Sub-Analysis Shows Consistent Results in Complex PCI Patients Watch now
EuroPCR 22: CRUZ-HBR Indicates Use Of Supraflux™ Cruz Stent Is Favourable Watch now
EuroPCR 22: ASTRO-TAVI Shows Improved Neurological Outcomes With Neurointervention Watch now
EuroPCR 22: Short-Term Clinical Outcomes of ACURATE neo2™ Watch now
EuroPCR 22: DECISION QFR Shows Increased Practicability and Shorter Procedure Time for Revasc. Watch now
EuroPCR 22: SYNERGY™ Non-inferior to BioMatrix NeoFlex in OCT SORT-OUT VIII Watch now
EuroPCR 22: ROLEX Study Finds Promising Results in CAD Pts With the Resolute Onyx Watch now
EuroPCR 22: Balloon Vs Self-Expanding Valves in Valve-in-Valve TAVI Watch now
EuroPCR 22: MitraClip in Atrial Functional Mitral Regurgitation Watch now
EuroPCR 22: SCB with Micro-Reservoir Technology in Coronary Lesions Watch now
EuroPCR 22: FORWARD PRO Study Shows No Durability Issues After 3 Years Watch now
EuroPCR 22: DEB & DES in the Treatment of Diffuse CAD Watch now
EuroPCR 22: EASTBOURNE Registry indicates Satefy of Sirolimus-Coated Balloon Watch now
EuroPCR 22: JenaValve TAVR System for the Treatment of Aortic Regurgitation Watch now
EuroPCR 22: Transcatheter Tricuspid Valve Repair with PASCAL System Watch now
EuroPCR 2022: ALIGN-EFS Finds 100% Procedural Success Rate Using JenaValve Trilogy in Pts With AS Watch now

Faculty Biographies

Michael Mæng

View full profile

Transcript

- My name is Michael Maeng. I'm an Interventional Cardiologist at Aarhus University Hospital, in Denmark. And I'm here to talk about the SORT-OUT VIII trial, with five years follow up.

Aim of This Study

The aim of the study is to compare two drug-eluting stents which both have bioabsorbable polymers. The first one is the synergy stent which is an everolimus eluting, drug-eluting stent. And the other one is the BioMatrix NeoFlex stent which eludes biolimus.

Study Design and Patient Population

The study design is an all-comer trial. It means that there were very few exclusion and inclusion criteria. Basically, we included all patients who were going to have a stent and who we thought would survive the first year. So we included two thousand seven hundred and sixty four patients, and they were randomised one to one to these two drug-eluting stents.

Key Findings

The key findings the study is that in synergy everolimus-eluting stent was non-inferior to the biolimus-eluting BioMatrix Neoflex stent at five years follow up. And importantly a key secondary endpoint was very late stent thrombosis and we saw very few events at one to five year follow up for both stent types.

Take-Home Messages

The take home message from this study is that both stent types that we examine in this study had very good results and the two stents were non-inferior to each other. So both stents can be used in our daily clinic practice and have very low rates of very late events, especially very late stent thrombosis.

Further Research Required and Next Steps

The future in, in this field is to make sure that the new stent types that comes out also have very low low rates of very late events and and have good results also in the long term. But I think another component in the future is to examine if these stents can also have very good results with lower time periods with dual antiplatelet therapy, like can we reduce the duration of dual antiplatelet therapy to six months or three months in, in with these stent types that will be the future questions.